| Document |
Document Title |
|
WO/2016/058559A1 |
Disclosed is a new polyolefin catalyst and preparation therefor. Specifically, disclosed is a catalytic system comprising a new complex of iron, cobalt, nickel, palladium, and platinum. In the presence of the catalytic system, oily polye...
|
|
WO/2016/055858A1 |
The present application relates to compounds of formula (I), (la), or (lb) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Αβ-related pathologies such as Down's ...
|
|
WO/2016/049774A1 |
Urea-based and bis-urea based compounds and analogues thereof are disclosed. These compounds are useful in the treatment of androgen-dependent diseases or disorders and androgen receptor-mediated diseases or disorders. Specifically, the ...
|
|
WO/2016/044770A1 |
Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. P...
|
|
WO/2016/044777A1 |
Compounds having a structure of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R3c, R4a, R4b, R5, R6, Z and X are as defined herein are provided. Pharmaceutical composit...
|
|
WO/2016/038500A1 |
The present invention relates to solid forms of 6-carboxy-2-(3,5-dichlorophenyl)- benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to t...
|
|
WO/2016/038632A1 |
The present invention disclose a single step one pot process for synthesis of oxazoline and imidazole derivatives from glycerol using solid acid metal catalyst with improved yield.
|
|
WO/2016/034134A1 |
Disclosed are heteroaryl derivatives, pharmaceutical composition and uses in the manufacture of a medicine for treating respiratory diseases, especially for chronic obstructive pulmonary disease (COPD).
|
|
WO/2016/021706A1 |
A compound represented by formula (I) or a salt thereof that has a blood LDL cholesterol-lowering action and is useful as an active ingredient of a drug (R1 indicates a C1-6 alkyl group, halogen atom, or the like; A indicates a phenylene...
|
|
WO/2016/015593A1 |
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or ...
|
|
WO/2016/016370A1 |
The invention pertains to novel FLT3receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.
|
|
WO/2016/013033A1 |
The present invention discloses a novel vinylic 3-amino-1,2 diol compounds of formula (I) and a one pot cost-effective process for the synthesis of vinylic-3-amino-1,2-diols of formula (I) which comprises tandem α-amination-benzoyloxyal...
|
|
WO/2016/013633A1 |
A compound represented by formula (I) or a salt thereof has an excellent noxious organism control activity, particularly an excellent miticidal activity and/or an excellent insecticidal activity, is highly safe, and can be synthesized in...
|
|
WO/2016/010538A1 |
Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the com...
|
|
WO/2016/001204A1 |
Primarily, the present invention relates to compounds of the formula (I) defined below and to the use thereof as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant g...
|
|
WO/2015/197640A1 |
The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRP.M8), and having formula (I). Said compounds are useful in the treatment of diseases associated wi...
|
|
WO/2015/184731A1 |
The invention provides fluoro-substituted chiral side chain-containing 2-arylbenzoheterocyclic compounds having affinity with Aβ plaque. The structural general formula of the compounds is shown as Formula (I), wherein X is N; Y is S or ...
|
|
WO/2015/181380A1 |
The present disclosure relates to cyclopropyl compounds of general formula (I), wherein R1, and R2 are as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to ...
|
|
WO/2015/173169A1 |
The present invention relates to substituted benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in whi...
|
|
WO/2015/172196A1 |
Novel heterocyclic compounds are provided which display useful efficacy in the treatment of diseases caused by trypanosomatids. Particularly, the compounds of the invention are useful in the treatment of HAT and/or Chagas disease and/or ...
|
|
WO/2015/173168A1 |
The present invention relates to benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulatio...
|
|
WO/2015/169908A1 |
The present invention relates to thiol-protected amino acid derivatives of formulae (I) and (II), peptides and block-copolymers containing the compounds and methods for preparing same. The present invention also relates to core-shell par...
|
|
WO/2015/170704A1 |
The present invention provides a novel polymer and a method for producing same. Provided are: a polymer that contains a structural unit represented by general formula (2): (In the formula, R1 is a hydrogen atom or an organic group. R2 an...
|
|
WO/2015/162538A1 |
The invention relates to heterocyclic compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their pharmaceutical compositions for use in medicine for the treatment of ...
|
|
WO/2015/162558A1 |
The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-med...
|
|
WO/2015/163604A1 |
The present invention relates to a novel selective androgen receptor agonist, a preparing method thereof, and a pharmaceutical composition containing a pharmaceutically effective amount thereof. The selective androgen receptor agonists o...
|
|
WO/2015/161830A1 |
Provided herein are novel heteroaromatic derivatives, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a prodrug, a pharmaceutically acceptable salt or a prodrug thereof, and pharmaceutical composition...
|
|
WO/2015/157927A1 |
Disclosed is a new florfenicol synthesizing method. The method synthesizes florfenicol products meeting requirements of the Drug Administration by a series of combinations of cyclization, selective reduction, fluorinated open ring, depro...
|
|
WO/2015/158204A1 |
The present invention relates to amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof. Specifically, the present invention relates to amide derivatives represented...
|
|
WO/2015/158191A1 |
Disclosed is a method for stereoselectively synthesizing hypolipidemic drug ezetimibe (I), comprising the following steps: a) an 4-(4-fluorobenzoyl)-1-butanoic acid (II) reacts with a chiral auxiliary (III) to obtain a ketone of a formul...
|
|
WO/2015/150995A1 |
Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of tre...
|
|
WO/2015/143653A1 |
The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of...
|
|
WO/2015/143652A1 |
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, ...
|
|
WO/2015/138969A1 |
Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subjec...
|
|
WO/2015/136947A1 |
The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in th...
|
|
WO/2015/133511A1 |
Provided is an endoparasite control agent that includes, as an active ingredient, a carboxamide derivative represented by general formula (I) or salts thereof in order to provide a novel endoparasite control agent such as an insecticide ...
|
|
WO/2015/128358A1 |
The present invention relates to azoline compounds of formula (I) wherein A, B1, B2, B3, G1, G2, X1, R1, R3a, R3b, Rg1 and Rg2 are as defined in the claims and the description. The compounds are useful for combating or controlling invert...
|
|
WO/2015/128504A1 |
The present invention relates to a process for the synthesis of 2,4-diamino-3(S)-hydroxycarboxylic acid derivatives from 5-hydroxyectoine.
|
|
WO/2015/124934A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, Formula (I) wherein L,X, Ra, Rb, R 1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical c...
|
|
WO/2015/117912A1 |
Compounds of formula (I), wherein (II) is a five-membered, aromatic ring system which may contain 2 or 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur,and where each ring system may not contain more than ...
|
|
WO/2015/115826A1 |
The present invention relates to a novel benzoxazole derivative having an effect of preventing or treating pruritus in skin disorders, and a method of preparing the same. Due to having excellent activity in improving pruritus, the benzox...
|
|
WO/2015/115650A1 |
Provided is a method for producing an optically active carboxylic acid ester at a high yield and with high enantioselectivity using dynamic kinetic resolution, said optically active carboxylic acid ester having an α-nitrogen substituent...
|
|
WO/2015/116786A1 |
In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another asp...
|
|
WO/2015/109666A1 |
Disclosed are an ester group-containing aromatic propionamide compound, and a preparation method therefor and uses thereof, and provides a chemical structure formula of the new ester group-containing aromatic propionamide compound. The c...
|
|
WO/2015/108038A1 |
The present invention addresses the problem of providing: a compound which is useful for the prevention or treatment of hyperphosphatemia or a hyperphosphatemia-related disease, or a pharmacologically acceptable salt of the compound; and...
|
|
WO/2015/106674A1 |
The present invention relates to a crystal form 1 of anacetrapib. Compared with the prior art, the crystal form 1 of anacetrapib of the present invention has a better crystal form stability, is easily stored, and is suitable for use as a...
|
|
WO/2015/108136A1 |
The present invention provides: a novel α-substituted glycinamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the compound or the pharmacologically acceptable salt; and a use of the...
|
|
WO/2015/107541A1 |
The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use ...
|
|
WO/2015/103526A1 |
Disclosed are PARP-1 inhibitors, which can be 18 F-labeled for use as tracers in positron emission tomographic (PET) imaging. Further disclosed are methods of synthesis. Of the compounds synthesized, 2-[p-(2-Fluoroethoxy)phenyl]-1.3.10-t...
|
|
WO/2015/102369A1 |
The present invention relates to a compound represented by chemical formula (1), a pharmaceutically acceptable salt thereof, a hydrate, a solvate, a prodrug, a tautomer, an enantiomer, or a pharmaceutically acceptable diastereomer, a met...
|
